One of the 2020 competition “Wanted: Life Sciences Innovator!” winners – Cumulatis joined the Life Sciences Digital Innovation Hub (LS DIH) cluster.
The main activity of the company is research and application of natural sciences and engineering. In recent years, the company has grown quite rapidly and contributed to innovations in the life sciences sector. Cumulatis team developed a prototype and pre-clinical study of a non-invasive monitoring device for Covid-19 patients at a rapid pace, just a quarter of a month after raising funding. “By joining the Life Sciences Digital Innovation Hub cluster, we hope to expand interdisciplinary relations and contribute to the development of partnerships between life sciences companies in Lithuania and abroad with our existing bioengineering competencies,” says Renaldas Urniežius, head of the company.
Cumulatis develops bioengineering solutions for bioreactor systems from flask experiments in laboratories to industrial installations. The solutions developed in the company are validated by culturing cultures of microorganisms (recombinant E.Coli, mammalian, and stem cells) and verifying them in macroorganisms, looking for potential applications in medicine. The company also participates in commissioned research and technology transfer activities with partners in Lithuania and abroad.
Gediminas Pauliukevičius, CEO of Northtown Vilnius, which coordinates the activities of the LS DIH cluster, has no doubt that Cumulatis addition to the cluster will benefit both the startup and cluster members, and the Cumulatis team’s competencies will expand and supplement those already in place. “The specifics of the company’s activities clearly show that Cumulatis will have the opportunity to effectively cooperate with other members of the cluster and life sciences companies, which, like the cluster, are located in the Vilnius City Innovation Industrial Park. Such cooperation and incentive to create and develop new solutions for the life sciences industry is one of the most important goals of the cluster, ”says G. Pauliukevičius.
The LS DIH cluster was established in 2019 in order to strengthen the development of life sciences companies, cooperation, and foster synergies in the development of new products. Currently, the cluster unites 16 partners, including Northtown Vilnius, Vilnius University Life Sciences Center, Vilnius City Municipality, Baltic Institute of Advanced Technologies, well-known biotechnology companies CasZyme, Droplet Genomics, Bioanalizės sistemos, Inlita, Diagnolita, Experimentica, Sanobiotec, Institute of Infectious Diseases and Pathogenic Microbiology, Grida, Biomatter Designs, artificial intelligence startup Three Thirds.